

# ICD-10 CODING BOOKLET

Your resource to ICD-10 diagnosis coding for patients with established cardiovascular disease (CVD) or familial hypercholesterolemia (FH) who require additional lowering of LDL-C



## Indications

### Repatha® is indicated:

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C
- As an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C

The safety and effectiveness of Repatha® have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia.

## Important Safety Information

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please [click here](#) to see additional Important Safety Information on page 17.

 **Repatha**<sup>®</sup>  
(evolocumab) injection  
140 mg/mL

# Hyperlipidemia and Ischemic Heart Disease

## Primary ICD-10 Codes

### Disorders of lipoprotein metabolism and other lipidemias

- E78.00 Pure hypercholesterolemia, unspecified
- E78.01 Familial hypercholesterolemia
- E78.2 Mixed hyperlipidemia
- E78.4 Other hyperlipidemia
- E78.5 Hyperlipidemia, unspecified

## Secondary ICD-10 Codes

### Atherosclerosis and atherosclerotic heart disease

- I25.10 Atherosclerotic heart disease of native coronary artery without angina pectoris
- I25.110 Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
- I25.111 Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
- I25.118 Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
- I25.119 Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
- I25.700 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
- I25.701 Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm

- I25.708 Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
- I25.709 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
- I25.710 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
- I25.711 Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.718 Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris
- I25.719 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
- I25.720 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris
- I25.721 Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.728 Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris
- I25.729 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
- I25.730 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris
- I25.731 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.738 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris
- I25.739 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
- I25.750 Atherosclerosis of native coronary artery of transplanted heart with unstable angina
- I25.751 Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm

## Important Safety Information

- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please [click here](#) to see additional Important Safety Information on page 17.

## Ischemic Heart Disease (*cont'd*)

- I25.758 Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
- I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
- I25.760 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
- I25.761 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm
- I25.768 Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris
- I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
- I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris
- I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris
- I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris
- I25.810 Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
- I25.811 Atherosclerosis of native coronary artery of transplanted heart without angina pectoris
- I25.812 Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris

### ➤ Ischemic heart disease (other)

- I20.8 Other forms of angina pectoris
- I20.9 Angina pectoris, unspecified
- I23.7 Postinfarction angina
- I24.0 Acute coronary thrombosis not resulting in myocardial infarction
- I24.8 Other forms of acute ischemic heart disease
- I25.2 Old myocardial infarction
- I25.3 Aneurysm of heart
- I25.41 Coronary artery aneurysm
- I25.42 Coronary artery dissection
- I25.5 Ischemic cardiomyopathy
- I25.6 Silent myocardial ischemia
- I25.82 Chronic total occlusion of coronary artery
- I25.83 Coronary atherosclerosis due to lipid rich plaque
- I25.84 Coronary atherosclerosis due to calcified coronary lesion
- I25.89 Other forms of chronic ischemic heart disease
- I25.9 Chronic ischemic heart disease, unspecified

### Important Safety Information

- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please [click here](#) to see additional Important Safety Information on page 17.

# Ischemic Heart Disease (*cont'd*) and Cerebrovascular Diseases



## ➤ **ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction**

- I21.01** ST elevation (STEMI) myocardial infarction involving left main coronary artery
- I21.02** ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
- I21.09** ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
- I21.11** ST elevation (STEMI) myocardial infarction involving right coronary artery
- I21.19** ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
- I21.21** ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
- I21.29** ST elevation (STEMI) myocardial infarction involving other sites
- I21.3** ST elevation (STEMI) myocardial infarction of unspecified site
- I21.4** Non-ST elevation (NSTEMI) myocardial infarction
- I22.0** Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
- I22.1** Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
- I22.2** Subsequent non-ST elevation (NSTEMI) myocardial infarction
- I22.8** Subsequent ST elevation (STEMI) myocardial infarction of other sites
- I22.9** Subsequent ST elevation (STEMI) myocardial infarction of unspecified site

## ➤ **Presence of cardiac and vascular implants and grafts and other postprocedural states**

- Z95.1** Presence of aortocoronary bypass graft
- Z95.5** Presence of coronary angioplasty implant and graft
- Z98.61** Coronary angioplasty status

## ➤ **Occlusion and stenosis of precerebral and cerebral arteries, not resulting in cerebral infarction**

- I65.01** Occlusion and stenosis of right vertebral artery
- I65.02** Occlusion and stenosis of left vertebral artery
- I65.03** Occlusion and stenosis of bilateral vertebral arteries
- I65.09** Occlusion and stenosis of unspecified vertebral artery
- I65.1** Occlusion and stenosis of basilar artery
- I65.21** Occlusion and stenosis of right carotid artery
- I65.22** Occlusion and stenosis of left carotid artery
- I65.23** Occlusion and stenosis of bilateral carotid arteries
- I65.29** Occlusion and stenosis of unspecified carotid artery
- I65.8** Occlusion and stenosis of other precerebral arteries
- I65.9** Occlusion and stenosis of unspecified precerebral artery
- I66.01** Occlusion and stenosis of right middle cerebral artery
- I66.02** Occlusion and stenosis of left middle cerebral artery
- I66.03** Occlusion and stenosis of bilateral middle cerebral arteries
- I66.09** Occlusion and stenosis of unspecified middle cerebral artery
- I66.11** Occlusion and stenosis of right anterior cerebral artery
- I66.12** Occlusion and stenosis of left anterior cerebral artery

## **Important Safety Information**

- **Adverse Reactions in Primary Hyperlipidemia:** From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Please [click here](#) to see additional Important Safety Information on page 17.

## Cerebrovascular Diseases (*cont'd*)

- I66.13 Occlusion and stenosis of bilateral anterior cerebral arteries
- I66.19 Occlusion and stenosis of unspecified anterior cerebral artery
- I66.21 Occlusion and stenosis of right posterior cerebral artery
- I66.22 Occlusion and stenosis of left posterior cerebral artery
- I66.23 Occlusion and stenosis of bilateral posterior cerebral arteries
- I66.29 Occlusion and stenosis of unspecified posterior cerebral artery
- I66.3 Occlusion and stenosis of cerebellar arteries
- I66.8 Occlusion and stenosis of other cerebral arteries
- I66.9 Occlusion and stenosis of unspecified cerebral artery

### ➤ Cerebrovascular diseases (other)

- I67.2 Cerebral atherosclerosis
- I67.5 Moyamoya disease
- I67.81 Acute cerebrovascular insufficiency
- I67.82 Cerebral ischemia
- I67.89 Other cerebrovascular disease
- I67.9 Cerebrovascular disease, unspecified
- I68.0 Cerebral amyloid angiopathy
- I68.8 Other cerebrovascular disorders in diseases classified elsewhere

### ➤ Cerebral infarction

- I63.00 Cerebral infarction due to thrombosis of unspecified precerebral artery
- I63.011 Cerebral infarction due to thrombosis of right vertebral artery
- I63.012 Cerebral infarction due to thrombosis of left vertebral artery
- I63.019 Cerebral infarction due to thrombosis of unspecified vertebral artery
- I63.02 Cerebral infarction due to thrombosis of basilar artery
- I63.031 Cerebral infarction due to thrombosis of right carotid artery
- I63.032 Cerebral infarction due to thrombosis of left carotid artery
- I63.039 Cerebral infarction due to thrombosis of unspecified carotid artery
- I63.09 Cerebral infarction due to thrombosis of other precerebral artery
- I63.20 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
- I63.211 Cerebral infarction due to unspecified occlusion or stenosis of right vertebral arteries
- I63.212 Cerebral infarction due to unspecified occlusion or stenosis of left vertebral arteries
- I63.219 Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries

### Important Safety Information

- **Adverse Reactions in Primary Hyperlipidemia:** Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha<sup>®</sup>-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha<sup>®</sup> and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please [click here](#) to see additional Important Safety Information on page 17.

## Cerebrovascular Diseases (*cont'd*)

### ➤ Cerebral infarction (*cont'd*)

- I63.22** Cerebral infarction due to unspecified occlusion or stenosis of basilar arteries
- I63.231** Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
- I63.232** Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
- I63.239** Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
- I63.29** Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries
- I63.30** Cerebral infarction due to thrombosis of unspecified cerebral artery
- I63.311** Cerebral infarction due to thrombosis of right middle cerebral artery
- I63.312** Cerebral infarction due to thrombosis of left middle cerebral artery
- I63.319** Cerebral infarction due to thrombosis of unspecified middle cerebral artery
- I63.321** Cerebral infarction due to thrombosis of right anterior cerebral artery
- I63.322** Cerebral infarction due to thrombosis of left anterior cerebral artery
- I63.329** Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
- I63.331** Cerebral infarction due to thrombosis of right posterior cerebral artery
- I63.332** Cerebral infarction due to thrombosis of left posterior cerebral artery
- I63.339** Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
- I63.341** Cerebral infarction due to thrombosis of right cerebellar artery
- I63.342** Cerebral infarction due to thrombosis of left cerebellar artery
- I63.349** Cerebral infarction due to thrombosis of unspecified cerebellar artery
- I63.39** Cerebral infarction due to thrombosis of other cerebral artery
- I63.50** Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
- I63.511** Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
- I63.512** Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
- I63.519** Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
- I63.521** Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
- I63.522** Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery
- I63.529** Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery
- I63.531** Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery
- I63.532** Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery
- I63.539** Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery
- I63.541** Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery
- I63.542** Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery

### Important Safety Information

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Please [click here](#) to see additional Important Safety Information on page 17.

# Cerebrovascular Diseases (*cont'd*) and Diseases of Arteries, Arterioles, and Capillaries



- I63.549** Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery
- I63.59** Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
- I63.8** Other cerebral infarction
- I63.9** Cerebral infarction, unspecified

## ➤ Transient cerebral ischemic attack

- Z86.73** Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
- G45.8** Other transient cerebral ischemic attacks and related syndromes
- G45.9** Transient cerebral ischemic attack, unspecified

## ➤ History of transient ischemic attack (TIA) or cerebral infarction without residuals

- Z86.73** Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

## ➤ Vascular syndromes of brain in cerebrovascular diseases

- G46.0** Middle cerebral artery syndrome
- G46.1** Anterior cerebral artery syndrome

- G46.2** Posterior cerebral artery syndrome
- G46.3** Brain stem stroke syndrome
- G46.4** Cerebellar stroke syndrome
- G46.5** Pure motor lacunar syndrome
- G46.6** Pure sensory lacunar syndrome
- G46.7** Other lacunar syndromes
- G46.8** Other vascular syndromes of brain in cerebrovascular diseases

## ➤ Atherosclerosis

- I70.0** Atherosclerosis of aorta
- I70.1** Atherosclerosis of renal artery
- I70.201** Unspecified atherosclerosis of native arteries of extremities, right leg
- I70.202** Unspecified atherosclerosis of native arteries of extremities, left leg
- I70.203** Unspecified atherosclerosis of native arteries of extremities, bilateral legs
- I70.208** Unspecified atherosclerosis of native arteries of extremities, other extremity
- I70.209** Unspecified atherosclerosis of native arteries of extremities, unspecified extremity
- I70.211** Atherosclerosis of native arteries of extremities with intermittent claudication, right leg
- I70.212** Atherosclerosis of native arteries of extremities with intermittent claudication, left leg

## Important Safety Information

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



## ➤ Atherosclerosis (*cont'd*)

- 170.213** Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs
- 170.218** Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity
- 170.219** Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity
- 170.221** Atherosclerosis of native arteries of extremities with rest pain, right leg
- 170.222** Atherosclerosis of native arteries of extremities with rest pain, left leg
- 170.223** Atherosclerosis of native arteries of extremities with rest pain, bilateral legs
- 170.228** Atherosclerosis of native arteries of extremities with rest pain, other extremity
- 170.229** Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity
- 170.231** Atherosclerosis of native arteries of right leg with ulceration of thigh
- 170.232** Atherosclerosis of native arteries of right leg with ulceration of calf
- 170.233** Atherosclerosis of native arteries of right leg with ulceration of ankle
- 170.234** Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
- 170.235** Atherosclerosis of native arteries of right leg with ulceration of other part of foot
- 170.238** Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg
- 170.239** Atherosclerosis of native arteries of right leg with ulceration of unspecified site
- 170.241** Atherosclerosis of native arteries of left leg with ulceration of thigh
- 170.242** Atherosclerosis of native arteries of left leg with ulceration of calf
- 170.243** Atherosclerosis of native arteries of left leg with ulceration of ankle
- 170.244** Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
- 170.245** Atherosclerosis of native arteries of left leg with ulceration of other part of foot
- 170.248** Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg
- 170.249** Atherosclerosis of native arteries of left leg with ulceration of unspecified site
- 170.25** Atherosclerosis of native arteries of other extremities with ulceration
- 170.261** Atherosclerosis of native arteries of extremities with gangrene, right leg
- 170.262** Atherosclerosis of native arteries of extremities with gangrene, left leg
- 170.263** Atherosclerosis of native arteries of extremities with gangrene, bilateral legs
- 170.268** Atherosclerosis of native arteries of extremities with gangrene, other extremity
- 170.269** Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity
- 170.291** Other atherosclerosis of native arteries of extremities, right leg
- 170.292** Other atherosclerosis of native arteries of extremities, left leg
- 170.293** Other atherosclerosis of native arteries of extremities, bilateral legs
- 170.298** Other atherosclerosis of native arteries of extremities, other extremity

## Important Safety Information

- **Adverse Reactions in HoFH:** In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.

Please [click here](#) to see additional Important Safety Information on page 17.



# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.299** Other atherosclerosis of native arteries of extremities, unspecified extremity
- I70.301** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- I70.302** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- I70.303** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- I70.308** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- I70.309** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- I70.311** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.312** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.313** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.318** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.319** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.321** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg
- I70.322** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg
- I70.323** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.328** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity
- I70.329** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.331** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh
- I70.332** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf
- I70.333** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle
- I70.334** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.335** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot
- I70.338** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.339** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site
- I70.341** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh
- I70.342** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf
- I70.343** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle
- I70.344** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.345** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot

## Important Safety Information

- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



## ➤ Atherosclerosis (*cont'd*)

- I70.348** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.349** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site
- I70.35** Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration
- I70.361** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg
- I70.362** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg
- I70.363** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.368** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity
- I70.369** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.391** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- I70.392** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- I70.393** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- I70.398** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- I70.399** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- I70.401** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.402** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.403** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.408** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.409** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.411** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.412** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.413** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.418** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.419** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.421** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
- I70.422** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
- I70.423** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.428** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
- I70.429** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.431** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
- I70.432** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
- I70.433** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
- I70.434** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot

## Important Safety Information

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.435** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot
- I70.438** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.439** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site
- I70.441** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh
- I70.442** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf
- I70.443** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle
- I70.444** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.445** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot
- I70.448** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.449** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site
- I70.45** Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration
- I70.461** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg
- I70.462** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg
- I70.463** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.468** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity
- I70.469** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.491** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.492** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.493** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.498** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.499** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.501** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.502** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.503** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs

## Important Safety Information

- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



## ➤ Atherosclerosis (*cont'd*)

- I70.508** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.509** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.511** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.512** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.513** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.518** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.519** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.521** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg
- I70.522** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg
- I70.523** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.528** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity
- I70.529** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.531** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh
- I70.532** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf
- I70.533** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle
- I70.534** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.535** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.538** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.539** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.541** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh
- I70.542** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf
- I70.543** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle
- I70.544** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.545** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.548** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.549** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.55** Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration
- I70.561** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg
- I70.562** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg
- I70.563** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs

## Important Safety Information

- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.568** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity
- I70.569** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.591** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.592** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.593** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.598** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.599** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.601** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.602** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.603** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.608** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.609** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.611** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.612** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.613** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.618** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.619** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.621** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg
- I70.622** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg
- I70.623** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.628** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity
- I70.629** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.631** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh
- I70.632** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf
- I70.633** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle

## Important Safety Information

- **Adverse Reactions in Primary Hyperlipidemia:** From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



## ➤ Atherosclerosis (*cont'd*)

- I70.634** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.635** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.638** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.639** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.641** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh
- I70.642** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf
- I70.643** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle
- I70.644** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.645** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.648** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.649** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.65** Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration
- I70.661** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg
- I70.662** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg
- I70.663** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.668** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity
- I70.669** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.691** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.692** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.693** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.698** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.699** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.701** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.702** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.703** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.708** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.709** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.711** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.712** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.713** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.718** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity

## Important Safety Information

- **Adverse Reactions in Primary Hyperlipidemia:** Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please [click here](#) to see additional Important Safety Information on page 17.



# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.719** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.721** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg
- I70.722** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg
- I70.723** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.728** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity
- I70.729** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.731** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
- I70.732** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
- I70.733** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
- I70.734** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.735** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
- I70.738** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.739** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site
- I70.741** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh
- I70.742** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf
- I70.743** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle
- I70.744** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.745** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot
- I70.748** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.749** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site
- I70.75** Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration
- I70.761** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg
- I70.762** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg
- I70.763** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.768** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity

## Important Safety Information

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Please [click here](#) to see additional Important Safety Information on page 17.

# Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



## ➤ Atherosclerosis (*cont'd*)

- I70.769 Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.791 Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.792 Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.793 Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.798 Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.799 Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.8 Atherosclerosis of other arteries
- I70.90 Unspecified atherosclerosis
- I70.91 Generalized atherosclerosis
- I70.92 Chronic total occlusion of artery of the extremities

## ➤ Diseases of arteries, arterioles, and capillaries (other)

- I73.9 Peripheral vascular disease, unspecified

## ➤ Family History

- Z83.42 Family history of familial hypercholesterolemia

## ➤ Peripheral vascular angioplasty

- Z95.820 Peripheral vascular angioplasty status with implants and grafts
- Z98.62 Peripheral vascular angioplasty status

## ➤ Other lipid storage disorders

- E75.5 Other lipid storage disorders\*

\* Other lipid storage disorders include tendon xanthoma.

## Important Safety Information

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Please [click here](#) to see additional Important Safety Information on page 17.



## Indications

---

### Repatha<sup>®</sup> is indicated:

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C
- As an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C

The safety and effectiveness of Repatha<sup>®</sup> have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia.

## Important Safety Information

---

- **Contraindication:** Repatha<sup>®</sup> is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha<sup>®</sup>. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha<sup>®</sup>.
- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha<sup>®</sup>. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha<sup>®</sup>, treat according to the standard of care, and monitor until signs and symptoms resolve.
- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha<sup>®</sup> and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha<sup>®</sup>-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha<sup>®</sup>-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha<sup>®</sup> and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha<sup>®</sup> and more frequently than placebo) were: diabetes mellitus (8.8% Repatha<sup>®</sup>, 8.2% placebo), nasopharyngitis (7.8% Repatha<sup>®</sup>, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha<sup>®</sup>, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha<sup>®</sup> compared with 7.7% in patients that received placebo.

- **Adverse Reactions in HoFH:** In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha<sup>®</sup> and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.
- **Immunogenicity:** Repatha<sup>®</sup> is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha<sup>®</sup>.

**Reference:** Centers for Medicare & Medicaid Services. 2018 ICD-10 Codes Table and Index.

**Please see full [Prescribing Information](#).**

**AMGEN**<sup>®</sup>

Amgen  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799  
[www.amgen.com](http://www.amgen.com)

© 2021 Amgen Inc. All rights reserved. USA-145-82880 04/21

 **Repatha**<sup>®</sup>  
(evolocumab) injection  
140 mg/mL